Category Archives: Parkinson’s Treatment

Overview Wolff-Parkinson-White Syndrome - Patrick Tchou, MD What is Wolff-Parkinson-White Syndrome (WPW)? Normally, the heartbeat begins at the sinoatrial (SA) node, located in your right atrium. Continue reading →

IMAC Holdings, Inc. BRENTWOOD, Tenn., Sept Continue reading →

SAN CARLOS, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032, a novel, oral beta-2 adrenoceptor (2-AR) agonist. The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease. CST-2032 is administered in combination with CST-107, a -AR blocker, to minimize known side effects of 2-AR agonists. Continue reading →

Its not a run, its a walk. Its really a fun event Continue reading →

Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury GELEEN, Netherlands, Sept. Continue reading →

Scott Rider is now in a different kind of race, one that's taking him across the U.S. for Parkinson's research. Monday, he's stopping in Columbus. Continue reading →

Mercks neuroscience portfolio is thin and there hasnt been much in this part of the pharmaceutical giants pipeline since the failure of an Alzheimers disease drug in a pivotal clinical trial five years ago. Biotech company Cerevance has had success discovering and advancing a Parkinsons disease drug candidate and Merck now wants to tap the startups technology to see if it can yield similar results in Alzheimers Continue reading →

Lars von Trier has been diagnosed with Parkinsons disease at the age of 66, per a statement from his representatives. The filmmaker is receiving treatment and will be able to finish his next project, the highly anticipated third season of The Kingdom, but will be keeping a lower public profile in the future. Lars is in good spirits and is being treated for his symptoms and given treatment so he can complete Riget Exodus, the statement said. Continue reading →

Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA. The US Food and Drug Administration (FDA) sent a Complete Response Letter (CRL) regarding the supplemental new drug application (sNDA) for pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis (ADP), according to Acadia Pharmaceuticals.1 The CRL indicated that the FDA has completed review of the application and could not approve the sNDA in its present form. The FDA recommended that Acadia conduct an additional trial in ADP Continue reading →

BETHESDA, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. Continue reading →